The evolution of 'light touch' medicines regulation for nicotine vaping products in Australia.

IF 4 2区 医学 Q1 PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH
Coral E Gartner
{"title":"The evolution of 'light touch' medicines regulation for nicotine vaping products in Australia.","authors":"Coral E Gartner","doi":"10.1136/tc-2024-059237","DOIUrl":null,"url":null,"abstract":"<p><p>Nicotine vaping products (NVPs) have never been legal to sell as consumer products in Australia. However, a substantial illicit market in NVPs developed with retailers selling these products under the pretence of retailing nicotine-free vaping products (NFVPs), which were legal to sell in most states and territories until July 2024. Australia implemented a 'light touch' medicines regulation approach for NVPs in October 2021, in response to public concerns about a growing number of young people vaping while retaining access to NVPs for smoking cessation purposes. Substantial changes to the model were made throughout 2024, including the ending of general retail sales of NFVPs, strengthening the quality requirements for NVPs and dropping the prescription requirement for low-dose (≤20 mg/mL) NVPs. There have been several challenges to encouraging uptake of the model among both consumers and health practitioners, including low acceptability, concerns about legal liability and competition with a substantial illicit NVP market. Assuming the reforms implemented federally and by the states and territories are able to effectively curtail the illicit supply, it is unclear whether current consumers who are accessing NVPs illicitly will migrate to the legal pathway or stop NVP use. Success of the medical regulatory model will depend on support from NVP manufacturers, health practitioners, the public and policy makers. Other countries who may be considering implementing a 'light touch' medicines regulation model can learn from Australia's experience.</p>","PeriodicalId":23145,"journal":{"name":"Tobacco Control","volume":" ","pages":""},"PeriodicalIF":4.0000,"publicationDate":"2025-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Tobacco Control","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1136/tc-2024-059237","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH","Score":null,"Total":0}
引用次数: 0

Abstract

Nicotine vaping products (NVPs) have never been legal to sell as consumer products in Australia. However, a substantial illicit market in NVPs developed with retailers selling these products under the pretence of retailing nicotine-free vaping products (NFVPs), which were legal to sell in most states and territories until July 2024. Australia implemented a 'light touch' medicines regulation approach for NVPs in October 2021, in response to public concerns about a growing number of young people vaping while retaining access to NVPs for smoking cessation purposes. Substantial changes to the model were made throughout 2024, including the ending of general retail sales of NFVPs, strengthening the quality requirements for NVPs and dropping the prescription requirement for low-dose (≤20 mg/mL) NVPs. There have been several challenges to encouraging uptake of the model among both consumers and health practitioners, including low acceptability, concerns about legal liability and competition with a substantial illicit NVP market. Assuming the reforms implemented federally and by the states and territories are able to effectively curtail the illicit supply, it is unclear whether current consumers who are accessing NVPs illicitly will migrate to the legal pathway or stop NVP use. Success of the medical regulatory model will depend on support from NVP manufacturers, health practitioners, the public and policy makers. Other countries who may be considering implementing a 'light touch' medicines regulation model can learn from Australia's experience.

澳大利亚尼古丁电子烟产品“轻触式”药品监管的演变。
在澳大利亚,尼古丁电子烟产品(NVPs)从未作为消费品合法销售。然而,随着零售商以零售不含尼古丁的电子烟产品(NFVPs)为幌子销售这些产品,nvvps的非法市场发展起来,在2024年7月之前,这些产品在大多数州和地区都是合法销售的。澳大利亚于2021年10月对非处方药实施了“轻触式”药物监管方法,以回应公众对越来越多的年轻人一边吸电子烟,一边为了戒烟而继续使用非处方药的担忧。在整个2024年,该模型发生了重大变化,包括结束nfvp的一般零售销售,加强对NVPs的质量要求,并取消低剂量(≤20mg /mL) NVPs的处方要求。在鼓励消费者和保健从业人员采用这一模式方面存在若干挑战,包括可接受性低、对法律责任的关切以及与大量非法非麻醉药品市场的竞争。假设联邦政府以及各州和地区实施的改革能够有效地减少非法供应,目前尚不清楚非法获取NVP的消费者是否会转向合法途径或停止使用NVP。医疗监管模式的成功将取决于NVP制造商、卫生从业人员、公众和决策者的支持。其他可能正在考虑实施“轻触式”药品监管模式的国家可以借鉴澳大利亚的经验。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Tobacco Control
Tobacco Control 医学-公共卫生、环境卫生与职业卫生
CiteScore
9.10
自引率
26.90%
发文量
223
审稿时长
6-12 weeks
期刊介绍: Tobacco Control is an international peer-reviewed journal covering the nature and consequences of tobacco use worldwide; tobacco''s effects on population health, the economy, the environment, and society; efforts to prevent and control the global tobacco epidemic through population-level education and policy changes; the ethical dimensions of tobacco control policies; and the activities of the tobacco industry and its allies.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信